Ahead of the Game: Updates in Multi-Cancer Early Detection TestsPremiere Date: Wednesday, January 19, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Family Physicians (AAFP)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, January 19, 2023
|Lincoln D. Nadauld, MD, PhD (Moderator)
Vice President, Chief of Precision Health and Academics
St. George, UT
|Tomasz M. Beer, MD, FACP
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Division of Hematology/Medical Oncology
Deputy Director, Oregon Health & Science University (OHSU) Knight Cancer Institute
Chief Medical Officer, Center for Early Detection Advanced Research (CEDAR)
|John J. Russell, MD, FAAFP
Clinical Professor, Department of Family and Community Medicine
Thomas Jefferson University Sydney Kimmel Medical College
Department Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Cancer screenings are essential for early detection of some of the most common cancers, but unfortunately early screening tests have only been developed for five types of cancer. This leaves most types without a method of detection prior to symptom onset. However, new multi-cancer early detection (MCED) tests that can detect multiple types of cancer with a single blood test are available or in development. Early detection assays are also an essential tool to detect recurrence or metastasis when a cancer is in remission after therapy. When added to existing cancer screening tools, MCED tests have the potential to change the paradigm of cancer detection. Clinicians require education that equips them with the knowledge and skills to incorporate these tests into practice.
This CME Outfitters Live and OnDemand will feature expert faculty discussing the benefits and limitations of current cancer screening approaches as well as available and emerging MCED tests and the considerations that guide the use of these tests.
At the end of this CE activity, participants should be able to:
- Explain the benefits and limitations of the current cancer screening approach.
- Assess the emerging MCED tests in development.
- Recognize the clinical considerations regarding emerging blood tests for cancer detection.
Supported by an educational grant from GRAIL, Inc.
Primary care physicians, family physicians, PAs, nurse practitioners, oncologists, hematologists, nurses, and pharmacists
AAFP Credit (Family Physicians):
The AAFP has reviewed Ahead of the Game: Updates in Multi-Cancer Early Detection Tests and deemed it acceptable for up to 1 Online Only, enduring AAFP Prescribed credit. Term of Approval is from 01/19/2022 to 01/19/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nadauld reports he is a stock shareholder (directly purchased) in Clarified Precision Medicine and Invitae Corporation. He is CEO of Culmination Bio.
Dr. Beer reports he receives grants and research support from Alliance Foundation Trials, LLC; Astellas Pharma Inc.; Bayer; Boehringer Ingelheim; Corcept Therapeutics; Endocyte, Inc.; Freenome; Grail Inc.; Harpoon Therapeutics; Janssen Research & Development; Medivation; Sotio; Theraclone Sciences/OncoResponse; and Zenith Epigenetics. He serves as a consultant for Arvinas; Astellas Pharma Inc.; AstraZeneca; Bayer; Bristol Myers Squibb; Clovis Oncology; Constellation; Grail Inc.; Janssen; Myovant Sciences; Novartis; Pfizer Inc.; Sanofi; and Tolero. He is a stock shareholder in Arvinas and Salarius Pharmaceuticals.
Dr. Russell reports he is on the speakers bureau for Sanofi Pasteur. He is a consultant for Bayer; GlaxoSmithKline; Pfizer Inc. and Sanofi Pasteur.
Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer) has no disclosures to report.
David Modrak, PhD, (planning committee) has no disclosures to report.
Kathleen Blake, (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).